United Therapeutics Corporation
UTHR
株式のランク
#998
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
株価
$551.89
最終同期: 2026-10-20
時価総額
$23.67B
変化（1日）
1.61%
変化（1年）
30.61%
国
US
取引 United Therapeutics Corporation (UTHR)
カテゴリー
Healthcare
United Therapeutics Corporation（UTHR）の収益
Jun 2026 時点の収益 TTM: $3.15B
United Therapeutics Corporation の最新の財務報告によると、現在の収益 (TTM) は $3.15B です。2023 年には $2.33B の収益があり、これは 2022 年の $1.94B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
United Therapeutics Corporation の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.15B | 9.63% |
| 2024 | $2.88B | 23.63% |
| 2023 | $2.33B | 20.20% |
| 2022 | $1.94B | 14.88% |
| 2021 | $1.69B | 13.63% |
| 2020 | $1.48B | 2.38% |
| 2019 | $1.45B | -11.00% |
| 2018 | $1.63B | -5.65% |
| 2017 | $1.73B | 7.91% |
| 2016 | $1.60B | 9.08% |
| 2015 | $1.47B | 13.76% |
| 2014 | $1.29B | 15.36% |
| 2013 | $1.12B | 21.93% |
| 2012 | $916.08M | 23.26% |
| 2011 | $743.18M | 23.08% |
| 2010 | $603.83M | 63.26% |
| 2009 | $369.85M | 31.39% |
| 2008 | $281.50M | 33.45% |
| 2007 | $210.94M | 32.14% |
| 2006 | $159.63M | 37.71% |
| 2005 | $115.92M | 57.51% |
| 2004 | $73.59M | 37.96% |
| 2003 | $53.34M | 77.09% |
| 2002 | $30.12M | 425.50% |
| 2001 | $5.73M | 179.70% |
| 2000 | $2.05M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 300.20% |
US
|
|
| $2.23B | -29.37% |
US
|
|
| $15.74B | 399.11% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 90.88% |
NL
|
